Joseph E. Turk, Jr. Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock

NxStage Medical, Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 3,500 shares of NxStage Medical stock in a transaction that occurred on Friday, February 10th. The stock was sold at an average price of $28.36, for a total value of $99,260.00. Following the completion of the transaction, the president now owns 69,280 shares of the company’s stock, valued at approximately $1,964,780.80. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) opened at 28.48 on Tuesday. The company has a 50 day moving average price of $27.01 and a 200 day moving average price of $24.94. NxStage Medical, Inc. has a one year low of $13.49 and a one year high of $28.72. The company’s market cap is $1.84 billion.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

This story was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at http://sleekmoney.com/joseph-e-turk-jr-sells-3500-shares-of-nxstage-medical-inc-nxtm-stock/1659542.html.

Several research analysts have recently commented on the company. Jefferies Group LLC lifted their target price on NxStage Medical to $38.00 and gave the stock a “buy” rating in a research report on Monday, February 6th. Zacks Investment Research lowered NxStage Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 5th. Canaccord Genuity set a $31.00 target price on NxStage Medical and gave the stock a “buy” rating in a research report on Monday, January 23rd. Finally, Northland Securities set a $35.00 target price on NxStage Medical and gave the stock a “buy” rating in a research report on Friday, December 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $29.67.

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of NxStage Medical by 11.6% in the second quarter. Vanguard Group Inc. now owns 4,602,539 shares of the medical device company’s stock valued at $99,783,000 after buying an additional 478,459 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of NxStage Medical by 3.1% in the third quarter. BlackRock Fund Advisors now owns 1,879,138 shares of the medical device company’s stock valued at $46,960,000 after buying an additional 57,187 shares during the last quarter. Sectoral Asset Management Inc. boosted its position in shares of NxStage Medical by 11.0% in the second quarter. Sectoral Asset Management Inc. now owns 1,828,582 shares of the medical device company’s stock valued at $39,644,000 after buying an additional 181,273 shares during the last quarter. Victory Capital Management Inc. bought a new position in shares of NxStage Medical during the third quarter valued at $44,715,000. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of NxStage Medical by 10.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,660,469 shares of the medical device company’s stock valued at $41,495,000 after buying an additional 157,459 shares during the last quarter. Institutional investors own 97.26% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/joseph-e-turk-jr-sells-3500-shares-of-nxstage-medical-inc-nxtm-stock/1659542.html

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *